A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.
about
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and managementA comprehensive joint analysis of the long and short RNA transcriptomes of human erythrocytes.The soluble form of BMPRIB is a novel therapeutic candidate for treating bone related disorders.Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts.Experimental and investigational therapies for chemotherapy-induced anemia.Thalassemia 2016: Modern medicine battles an ancient disease.Current and future chemical therapies for treating anaemia in chronic kidney disease.2017 Clinical trials update in new treatments of β-thalassemia.Emerging drugs for the treatment of kidney disease-induced anemia.Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.Recent frustration and innovation in myelodysplastic syndrome.Detection of Sotatercept (ACE-011) in human serum by SAR-PAGE and western single blotting.Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.Antibody-based strategies for the detection of Luspatercept (ACE-536) in human serum.Emerging Therapies.
P2860
Q26796240-05296351-212A-43FD-85A9-60DE81813620Q35842890-8C69C74D-E526-419B-9901-A783F85181E0Q36432535-5AD42E87-07DD-40B3-A4C5-3E8702AF0CBFQ36799748-E49A6515-7E61-4BB2-8A22-28C60C7ABC6AQ38584639-A0C4E0C8-6F79-4E99-AF0D-20BD9F4B31AAQ38625435-9F469CFF-54A1-4631-B621-10AD1B7F1A10Q38690858-DE852184-A0DC-46A3-9F7E-79ABDD52DD1AQ38922283-F2198E30-97FB-469A-8F45-0B39A2291709Q38930912-C1E8F212-7178-4724-841C-0BD78B143DC2Q38946634-A9B6747A-D1EE-496E-A362-3BB79F0ED310Q40915310-F412C39E-E64D-405C-8ABE-AF9F552CF7B1Q42391622-D1DC8A84-7EFD-4EF2-9E9F-D07B3911E53AQ47342828-1BC152BB-892A-4022-9B8C-36B7AEF22CE1Q47548041-DD0D075D-E435-46F2-91A2-2D1F394AF353Q47742744-97622A08-DB1F-44D2-B6B2-ECCB4645FD99Q47773842-397A57A5-BCC6-48E6-A1DF-CF3B14CBA561Q49837060-45772C1A-68FE-4DC1-970B-7CD36F9F9374
P2860
A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase 1 study of ACE-536, a ...... iation, in healthy volunteers.
@ast
A phase 1 study of ACE-536, a ...... iation, in healthy volunteers.
@en
A phase 1 study of ACE-536, a ...... iation, in healthy volunteers.
@nl
type
label
A phase 1 study of ACE-536, a ...... iation, in healthy volunteers.
@ast
A phase 1 study of ACE-536, a ...... iation, in healthy volunteers.
@en
A phase 1 study of ACE-536, a ...... iation, in healthy volunteers.
@nl
prefLabel
A phase 1 study of ACE-536, a ...... iation, in healthy volunteers.
@ast
A phase 1 study of ACE-536, a ...... iation, in healthy volunteers.
@en
A phase 1 study of ACE-536, a ...... iation, in healthy volunteers.
@nl
P2093
P2860
P356
P1476
A phase 1 study of ACE-536, a ...... iation, in healthy volunteers.
@en
P2093
Amelia E Pearsall
Dawn M Wilson
Ingrid E Boyd
Kenneth M Attie
Mark J Allison
Matthew L Sherman
Ty McClure
P2860
P304
P356
10.1002/AJH.23732
P577
2014-04-26T00:00:00Z